| Bioactivity | HDAC8-IN-12 (compound 5k) is a non-hydroxamic acid, selective inhibitor of HDAC8 (IC50: 0.12 nM) and a potent inhibitor of breast cancer. HDAC8-IN-12 triggers anti-tumor immunity by activating T cells, increasing the proportion of M1 macrophages and decreasing the proportion of M2 macrophages. HDAC8-IN-12 (50 mg/kg) exerts tumor suppressive effects in an orthotopic mouse model of breast cancer[1]. |
| Target | IC50: 0.12 nM (HDAC8) |
| CAS | 3028095-13-5 |
| Formula | C16H17N3O5 |
| Molar Mass | 331.32 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer |
HDAC8-IN-12
CAS: 3028095-13-5 F: C16H17N3O5 W: 331.32
HDAC8-IN-12 (compound 5k) is a non-hydroxamic acid, selective inhibitor of HDAC8 (IC50: 0.12 nM) and a potent inhibitor
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.